Affymetrix Announces Court Order Directing Dismissal of Illumina Patent Infringement Lawsuits
15 December 2010 - 9:00PM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) (the “Company”) today announced
that the U.S. District Court for the Western District of Wisconsin
(the “Court”) has granted the company’s motion for summary judgment
that Affymetrix does not infringe the patents held by Illumina,
Inc. (NASDAQ: ILMN), and has directed that the patent infringement
lawsuits brought against the company by Illumina regarding U.S.
Patent Nos. 7,510,841 and 7,612,020 be dismissed and the cases
closed.
“We are pleased with the Court’s ruling, which confirms our
position that Illumina’s lawsuits were without merit,” said Rick
Runkel, Affymetrix’s Executive Vice President, General Counsel and
Secretary. “As a biotechnology company that invests significant
time, resources and expertise in R&D, we are committed to
conducting our business with the utmost integrity and believe that
the Court’s ruling underscores this commitment.”
About Affymetrix
Affymetrix technology is used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading
academic, government, and nonprofit research institutes. More than
1,900 systems have been shipped around the world and more than
22,000 peer-reviewed papers have been published using the
technology.
Affymetrix is headquartered in Santa Clara, Calif., and has
manufacturing facilities in Cleveland, Ohio, and Singapore. The
company has about 1,000 employees worldwide and maintains sales and
distribution operations across Europe and Asia. For more
information about Affymetrix, please visit
http://www.affymetrix.com.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Affymetrix, Inc. (NASDAQ): 0 recent articles
More Affymetrix, Inc. News Articles